Literature DB >> 18342968

Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study.

Katsuyuki Karasawa1, Makoto Sunamura, Atsutake Okamoto, Kenji Nemoto, Seiki Matsuno, Yasumasa Nishimura, Yuta Shibamoto.   

Abstract

Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p=0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18342968     DOI： 10.1016/j.radonc.2008.02.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  12 in total

Review 1.  Research opportunities in intraoperative radiation therapy: the next decade 2013-2023.

Authors:  F A Calvo; C V Sole; M E González; E D Tangco; J López-Tarjuelo; I Koubychine; J A Santos; J Pascau; R Herranz; C Ferrer
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

2.  Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole in vitro and in vivo.

Authors:  Hironobu Yasui; Nobuo Kubota; Junko Nishizumi; Yuri Sakai; Tohru Yamamori; Osamu Inanami
Journal:  Oncol Lett       Date:  2017-11-23       Impact factor: 2.967

Review 3.  Biological determinants of radioresistance and their remediation in pancreatic cancer.

Authors:  Parthasarathy Seshacharyulu; Michael J Baine; Joshua J Souchek; Melanie Menning; Sukhwinder Kaur; Ying Yan; Michel M Ouellette; Maneesh Jain; Chi Lin; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-02-27       Impact factor: 10.680

Review 4.  Modulation of the tumor vasculature and oxygenation to improve therapy.

Authors:  Dietmar W Siemann; Michael R Horsman
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

5.  Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.

Authors:  J Martin Brown; Maximilian Diehn; Billy W Loo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

Review 6.  Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.

Authors:  Everett J Moding; Yvonne M Mowery; David G Kirsch
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

Review 7.  The impact of hypoxia and its modification of the outcome of radiotherapy.

Authors:  Michael R Horsman; Jens Overgaard
Journal:  J Radiat Res       Date:  2016-03-16       Impact factor: 2.724

8.  Biological effects of hydrogen peroxide administered intratumorally with or without irradiation in murine tumors.

Authors:  Taiki Takaoka; Yuta Shibamoto; Masayuki Matsuo; Chikao Sugie; Taro Murai; Yasutaka Ogawa; Akifumi Miyakawa; Yoshihiko Manabe; Takuhito Kondo; Koichiro Nakajima; Dai Okazaki; Takahiro Tsuchiya
Journal:  Cancer Sci       Date:  2017-07-21       Impact factor: 6.716

Review 9.  Therapeutic targeting of the hypoxic tumour microenvironment.

Authors:  Dean C Singleton; Andrew Macann; William R Wilson
Journal:  Nat Rev Clin Oncol       Date:  2021-07-29       Impact factor: 66.675

Review 10.  Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?

Authors:  Yuta Shibamoto; Akifumi Miyakawa; Shinya Otsuka; Hiromitsu Iwata
Journal:  J Radiat Res       Date:  2016-03-22       Impact factor: 2.724
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.